Carcinoembryonic antigen, Mucin 1, and Brachyury (CEA/MUC1/Brachyury)

This target profile comprises a triad of tumor-associated antigens (TAAs)—Carcinoembryonic Antigen (CEA), Mucin 1 (MUC1), and Brachyury—that are simultaneously targeted to address tumor heterogeneity and metastatic potential. Carcinoembryonic antigen (CEACAM5) is a cell surface glycoprotein involved in cell adhesion and is highly overexpressed in various adenocarcinomas, particularly colorectal and pancreatic cancers [UniProt P06731]. Mucin 1 (MUC1) is a transmembrane glycoprotein that plays a role in cell signaling and mucosal protection, often found aberrantly glycosylated and overexpressed in breast and lung carcinomas [UniProt P15941]. Brachyury is a T-box transcription factor that acts as a master regulator of the epithelial-mesenchymal transition (EMT), a process that enables tumor cells to migrate, invade, and resist conventional therapies [PMID: 25103453]. Therapeutic strategies, such as the Tri-Ad5 adenovirus-based vaccine platform, utilize these three antigens to stimulate a robust, polyfunctional T-cell response. By targeting multiple antigens involved in both the structural integrity and the metastatic progression of the tumor, this approach aims to minimize the risk of immune escape and enhance the efficacy of immunotherapy in patients with advanced malignancies [PMID: 32044611, PMID: 30107329].

Other names

CEACAM5MUC-1T-box transcription factor TTCarcinoembryonic antigen-related cell adhesion molecule 5Mucin 1, cell surface associatedCD227Tri-Ad5 antigens

Induction of antigen-specific CD4+ and CD8+ T-cell mediated immune responses through the delivery of genetic sequences for CEA, MUC1, and Brachyury via viral vectors (e.g., Adenovirus 5) to antigen-presenting cells [PMID: 32044611, PMID: 28495915].